Brief: Adocia Expands Clinical Development To Obesity

Adocia SA

26/05/2021 06:39

May 26 (Reuters) - Adocia SA  ADOC.PA :
    * THREE PATENT FAMILIES HAVE BEEN FILED TO COVER NOVEL
HORMONAL
COMBINATIONS: PRAMLINTIDE-EXENATIDE AND GLUCAGON-EXENATIDE -
BOTH COMBINATIONS DEMONSTRATED PROMISING EFFECTS IN OBESITY
TREATMENT
    * ADOCIA EXPANDS CLINICAL DEVELOPMENT TO OBESITY WITH PATENT
APPLICATIONS ON SHORT-ACTING MULTIHORMONAL COMBINATIONS
ADMINISTERED BY PUMPS
    * ADMINISTERING SHORT-ACTING HORMONES BY A PUMP EMPOWERS
PATIENT,
WHO CAN OPTIMIZE BENEFIT/RISK RATIO OF THEIR TREATMENT
    * THESE FORMULATIONS COULD ALSO BE DEVELOPED FOR TREATMENT
OF
OTHER METABOLIC DISEASES SUCH AS NASH (NON-ALCOHOLIC
STEATO-HEPATITIS), TYPE 2 DIABETES OR NEURODEGENERATIVE DISEASES

Source text for Eikon:  ID:nGNX7Cdf7K 
Further company coverage:  ADOC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))